Value proposition

NEW FRONTIERS IN NEUROSCIENCE

Expertise, Experience, Innovation, Vision, Values.
Neurentis PLC is a late-clinical stage UK biotech company, focusing on neuroscience and specialising in the development of novel treatments for mental health and other neurological and psychiatric diseases.

Our product pipeline is balanced with 3 products: 1) an advanced lead drug candidate, a prescription pharmaceutical (selegiline), in a transdermal patch, for the treatment of Treatment-Resistant Depression (TRD) in the last stages of drug development, 2) a small molecule agonist of the oxytocin receptors for the treatment of Autism, Chronic and Neuropathic Pain and addiction to alcohol and opioids and 3) a proprietary formula of natural ingredients which have demonstrated evidence in being efficacious, for supporting the mental health and boosting the central nervous system.

The company is run by experienced ex-pharma industry executives, with more than 30 years’ experience in the sector each. The company’s low-risk commercial strategy is to commercialize its products through collaborations with pharma companies around the world.

Pharmaceuticals, Biotech, Neuroscience, Neuropsychiatry, Depression, and Mental Health